Steris Stock News

The Zacks Medical - Instruments industry is growing on R&D investments. ALC, STE and ABMD are set to gain the most.

Investors are optimistic about STERIS' (STE) robust segmental growth and noteworthy acquisitions in the healthcare and pharmaceutical spaces.

Investors are optimistic about STERIS (STE) on impressive growth across its operating segments.

Investors are optimistic about STERIS' (STE) robust segmental performance and upbeat 2022 guidance.

Steris (STE) reported earnings 30 days ago. What's next for the stock?

STERIS' (STE) significant revenues from acquisitions of Key Surgical and Cantel Medical appear promising.

STERIS plc (Ireland) found using ticker (STE) now have 4 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 295 and 256 with a mean TP of 271. With the stocks previous close at 244.06 this indicates there is a potential upside of 11.0%. The 50 day MA is 232.78 and the 200 day moving average is 219.68. The company has a market cap of $24,549m. Visit the company website at: https://www.steris.com [stock_market_widget type="chart" template="basic" color="green" assets=STE" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $27,259m based on the market concensus. STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.

Is it the Wrigley''s gum of healthcare?

Is it the Wrigley's gum of healthcare?

Pune, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Global Surgical Display Market report delivers a complete overview of key components like drivers, limitations, historic and current trends, technical development, and future growth. Research report contains company analysis, size, share, revenue and sales of the company, current advancements. Surgical Display market analysis also focuses on the global key top industry players in the market, with details such as company profiles, capacity, production, price, cost, revenue. According to a study by Researcher, is anticipated to reach at USD 655.1 million in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 0.9% from 2021 to 2028. Get a Sample Copy of the Report at - https://www.absolutereports.com/enquiry/request-sample/20198842 The top players are concentrating mostly on technical developments in order to increase efficiency. The long-term growth patterns for this market can be taken by continuing the current development progresses and financial strength to participate in the best strategies.

The Rising Profits Estimates screen reveals hot stocks to watch, such as Costamare, Ares Management and Steris.

STERIS (STE) reports better-than-expected earnings for the third quarter of fiscal 2022 and robust segmental growth driving the top line.

Steris plc (NYSE: STE ) reported Q3 FY22 sales of $1.2 billion , +49% Y/Y, in line with the consensus of $1.2 billion. Constant currency organic revenue increased 9%. Adjusted EPS of $2.12, compared with the previous year''s third quarter of $1.73, beating the consensus of $1.97. Healthcare segment revenue grew 46% to $759.7 million, with $210.3 million added from acquisitions, reflecting an 84% increase in consumable revenue, … Full story available on Benzinga.com

STERIS plc. (STE) CEO Dan Carestio on Q3 2022 Results - Earnings Call Transcript